Article
Early Viral Response Predicts the Efficacy of Antiviral Triple Therapy with Simeprevir, Peg-Interferon and Ribavirin in Patients Infected with Hepatitis C Virus Genotype 1.
Digestive diseases (Basel, Switzerland) - 1 Oct 2015
Nishida Naoshi, Iwanishi Mina, Minami Tomohiro, Chishina Hirokazu, Arizumi Tadaaki, Takita Masahiro, Kitai Satoshi, Yada Norihisa, Ida Hiroshi, Hagiwara Satoru, Minami Yasunori, Ueshima Kazuomi, Sakurai Toshiharu, Kitano Masayuki, Kudo Masatoshi
Abstract excerpt
OBJECTIVES: Triple therapy using peg-interferon, ribavirin and simeprevir (PEG-IFN/RBV/SMV) has reportedly resulted in high-sustained virological response (SVR) rates in patients with chronic hepatitis C (CHC), especially in naïve cases and relapsers to prior PEG-IFN/RBV therapy. Here, we retrospectively analyzed the antiviral response associated with a triple regimen, in the context of early reduction of viral...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.